...
首页> 外文期刊>Clinical infectious diseases >Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.
【24h】

Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

机译:荟萃分析:艾滋病毒感染者与丙型肝炎相关的死亡率增加与艾滋病毒的病情发展无关。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: It is unclear whether coinfection with hepatitis C virus (HCV) increases mortality in patients with human immunodeficiency virus (HIV) infection during the era of highly active antiretroviral therapy (HAART). With use of a meta-analysis, we estimated the effect of HCV infection on HIV disease progression and overall mortality in the pre-HAART and HAART eras. METHOD: The PubMed and EMBASE databases were searched for studies published through 30 April 2008. Additional studies were identified from cited references. Studies reporting disease progression or mortality among HCV-HIV coinfected patients were selected. Cross-sectional studies, studies without HCV-negative control subjects, and studies involving children and/or patients who had undergone liver transplantation were excluded. Two authors reviewed articles and extracted data on the demographic characteristics of study populations and risk estimates. Meta-regression was used to explore heterogeneity. RESULTS: Ten studies from the pre-HAART era and 27 studies from the HAART era were selected. In the pre-HAART era, the risk ratio for overall mortality among patients with HCV-HIV coinfection, compared with that among patients with HIV infection alone, was 0.68 (95% confidence interval [CI], 0.53-0.87). In the HAART era, the risk ratio was 1.12 (95% CI, 0.82-1.51) for AIDS-defining events and 1.35 (95% CI, 1.11-1.63) for overall mortality among coinfected patients, compared with that among patients with HIV monoinfection. CONCLUSIONS: HCV coinfection did not increase mortality among patients with HIV infection before the introduction of HAART. In contrast, in the HAART era, HCV coinfection, compared with HIV infection alone, increases the risk of mortality, but not the risk of AIDS-defining events. Future studies should determine whether successful treatment of HCV infection could reduce this excess risk of mortality in coinfected patients.
机译:背景:目前尚不清楚在高效抗逆转录病毒疗法(HAART)时代,丙型肝炎病毒(HCV)合并感染是否会增加人类免疫缺陷病毒(HIV)感染患者的死亡率。通过荟萃分析,我们估计了在HAART前和HAART时代HCV感染对HIV疾病进展和总体死亡率的影响。方法:从PubMed和EMBASE数据库中搜索截至2008年4月30日发表的研究。从引用的参考文献中鉴定出其他研究。选择在HCV-HIV合并感染的患者中报告疾病进展或死亡率的研究。不包括横断面研究,无HCV阴性对照受试者的研究以及涉及儿童和/或接受肝移植的患者的研究。两位作者审阅了文章,并提取了有关研究人群的人口统计学特征和风险估计的数据。元回归被用来探索异质性。结果:选择了来自HAART前时代的十项研究和来自HAART时代的27项研究。在HAART之前的时代,HCV-HIV合并感染患者的总死亡率风险比与仅HIV感染患者的总风险比为0.68(95%置信区间[CI],0.53-0.87)。在HAART时代,与HIV单一感染患者相比,合并艾滋病毒感染者的总死亡率为1.12(95%CI,0.82-1.51),总死亡率为1.35(95%CI,1.11-1.63)。 。结论:引入HAART之前,HCV合并感染并未增加HIV感染患者的死亡率。相反,在HAART时代,HCV合并感染与单独的HIV感染相比增加了死亡的风险,但没有增加定义艾滋病事件的风险。未来的研究应确定成功治疗HCV感染是否可以降低合并感染患者的这种过度死亡风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号